Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Electra Therapeutics, Inc. is the issuer in a Schedule 13G reporting beneficial ownership by Redmile Group, LLC, Jeremy C. Green, and Redmile Biopharma Investments II, L.P. Redmile Group and Green each report beneficial ownership of 5,462,881 shares, or 8.7%; Redmile Biopharma Investments II directly owns 4,796,215 shares, or 7.6%.
The reported positions overlap: Redmile’s 5,462,881 shares include shares held by investment vehicles, including Redmile Biopharma Investments II. Redmile reports shared voting and dispositive power as investment manager, and Green as Redmile’s principal. Both disclaim beneficial ownership except to the extent of their pecuniary interest, if any. The percentages use 62,766,955 shares outstanding immediately after the initial public offering.
Key Figures
Beneficial ownership reported by Redmile Group and Jeremy C. Green:5,462,881 sharesReported beneficial ownership percentage for Redmile Group and Jeremy C. Green:8.7%Direct ownership by Redmile Biopharma Investments II, L.P.:4,796,215 shares+2 more
5 metrics
Beneficial ownership reported by Redmile Group and Jeremy C. Green5,462,881 sharesEach reported 8.7%; the positions include shares held by investment vehicles.
Reported beneficial ownership percentage for Redmile Group and Jeremy C. Green8.7%Each reported beneficial ownership of 5,462,881 shares.
Direct ownership by Redmile Biopharma Investments II, L.P.4,796,215 sharesReported as 7.6% of the class.
Reported beneficial ownership percentage for Redmile Biopharma Investments II, L.P.7.6%The partnership directly owns 4,796,215 shares.
Shares outstanding immediately after the initial public offering62,766,955 sharesBasis for the reported ownership percentages.
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting powerregulatory
"Shared power to vote or to direct the vote"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
dispositive powerregulatory
"Shared power to dispose or to direct the disposition"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
pecuniary interestfinancial
"except to the extent of its or his pecuniary interest, if any"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many ETRA shares did Redmile Group and Jeremy C. Green report?
Redmile Group and Jeremy C. Green each reported beneficial ownership of 5,462,881 shares, or 8.7%. Redmile’s reported position includes shares directly held by investment vehicles, including Redmile Biopharma Investments II.
How many ETRA shares did Redmile Biopharma Investments II own?
Redmile Biopharma Investments II, L.P. directly owned 4,796,215 shares, or 7.6%. The percentage is based on 62,766,955 shares outstanding immediately after the initial public offering.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Electra Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
284825106
(CUSIP Number)
09/21/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
284825106
1
Names of Reporting Persons
Redmile Group, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,462,881.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,462,881.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,462,881.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
8.7 %
12
Type of Reporting Person (See Instructions)
IA, OO
Comment for Type of Reporting Person: The information in Item 4 relating to the shares of common stock, $0.0001 par value per share, of the Issuer (the "Common Stock") that are or may be deemed beneficially owned by Redmile Group, LLC and the calculation of the percent of such class of securities is incorporated by reference herein.
SCHEDULE 13G
CUSIP Number(s):
284825106
1
Names of Reporting Persons
Jeremy C. Green
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED KINGDOM
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,462,881.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,462,881.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,462,881.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
8.7 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: The information in Item 4 relating to the shares of Common Stock that are or may be deemed beneficially owned by Jeremy Green and the calculation of the percent of such class of securities is incorporated by reference herein.
SCHEDULE 13G
CUSIP Number(s):
284825106
1
Names of Reporting Persons
Redmile Biopharma Investments II, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
4,796,215.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
4,796,215.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
4,796,215.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.6 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The information in Item 4 relating to the shares of Common Stock that are or may be deemed beneficially owned by Redmile Biopharma Investments II, L.P. and the calculation of the percent of such class of securities is incorporated by reference herein.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Electra Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
230 E. Grand Avenue Suite S-100 South San Francisco, CA 94080
Item 2.
(a)
Name of person filing:
Redmile Group, LLC
Jeremy C. Green
Redmile Biopharma Investments II, L.P.
(b)
Address or principal business office or, if none, residence:
Redmile Group, LLC
900 Larkspur Landing Circle, Suite 270
Larkspur, California 94939
Jeremy C. Green
c/o Redmile Group, LLC (NY Office)
45 W. 27th Street, Floor 11
New York, NY 10001
Redmile Biopharma Investments II, L.P.
c/o Redmile Group, LLC
900 Larkspur Landing Circle, Suite 270
Larkspur, California 94939
(c)
Citizenship:
Redmile Group, LLC: Delaware
Jeremy C. Green: United Kingdom
Redmile Biopharma Investments II, L.P.: Delaware
(d)
Title of class of securities:
Common Stock, $0.0001 par value per share
(e)
CUSIP Number(s):
284825106
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Redmile Group, LLC - 5,462,881 (1)
Jeremy C. Green - 5,462,881 (1)
Redmile Biopharma Investments II, L.P. - 4,796,215 (2)
(b)
Percent of class:
Redmile Group, LLC - 8.7% (3)
Jeremy C. Green - 8.7% (3)
Redmile Biopharma Investments II, L.P. - 7.6% (3)
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Redmile Group, LLC - 0
Jeremy C. Green - 0
Redmile Biopharma Investments II, L.P. - 0
(ii) Shared power to vote or to direct the vote:
Redmile Group, LLC - 5,462,881 (1)
Jeremy C. Green - 5,462,881 (1)
Redmile Biopharma Investments II, L.P. - 4,796,215 (2)
(iii) Sole power to dispose or to direct the disposition of:
Redmile Group, LLC - 0
Jeremy C. Green - 0
Redmile Biopharma Investments II, L.P. - 0
(iv) Shared power to dispose or to direct the disposition of:
Redmile Group, LLC - 5,462,881 (1)
Jeremy C. Green - 5,462,881 (1)
Redmile Biopharma Investments II, L.P. - 4,796,215 (2)
(1) All of such shares of Common Stock are directly owned by certain investment vehicles, including Redmile Biopharma Investments II, L.P. ("RBI II"), for which Redmile is the investment manager (the "Redmile Funds"). Redmile may be deemed to beneficially own these securities in its capacity as their investment manager with discretion to vote and dispose of all shares of Common Stock held by the Redmile Funds. Mr. Green also may be deemed to beneficially own these securities as the principal of Redmile. Redmile and Mr. Green each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest in such securities, if any.
(2) All of such shares of Common Stock are directly owned RBI II.
(3) Percentage based on 62,766,955 shares of Common Stock outstanding immediately after the initial public offering, as reported in the Issuer's Prospectus dated September 17, 2026 filed with the SEC on September 18, 2026.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See the response to Item 4.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Redmile Group, LLC
Signature:
/s/ Jeremy C. Green
Name/Title:
Managing Member
Date:
09/28/2026
Jeremy C. Green
Signature:
/s/ Jeremy C. Green
Name/Title:
Jeremy C. Green
Date:
09/28/2026
Redmile Biopharma Investments II, L.P.
Signature:
/s/ Jeremy C. Green
Name/Title:
Managing Member of Redmile Group, LLC, Managing Member of Redmile Biopharma Investments II (GP), LLC, General Partner of Redmile Biopharma Investments
